Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial.
- Resource Type
- Article
- Source
- In
EClinicalMedicine December 2019 17 - Subject
- Language
- ISSN
- 2589-5370